•  
  •  
 

Abstract

This comprehensive review synthesizes recent advances in cancer nanotherapy, focusing on 6 emerging categories: immunomodulation, gene/RNA delivery, theranostics, radiosensitization, biomimetic carriers, and artificial intelligence (AI)-guided formulations. These innovative platforms demonstrate transformative potential by overcoming key limitations of conventional cancer treatments. Immunomodulatory nanoparticles reprogram tumor microenvironments and convert immunologically ``cold'' tumors to ``hot'' responsive states. Gene delivery systems enable precise editing with >50% efficiency, while theranostic platforms integrate real-time imaging with targeted therapy. Radiosensitizers amplify local radiation dose by twofold, and biomimetic carriers achieve prolonged circulation through immune evasion. An AI-driven approaches optimize personalized formulations based on patient-specific biomarkers. Clinical evidence shows promising safety profiles with predominantly mild-to-moderate adverse events across multiple Phase I-III trials. While nanotherapy represents a paradigm shift in precision oncology, addressing manufacturing reproducibility, long-term safety, and regulatory harmonization remains essential for full clinical translation.

Article Type

Review

First Page

780

Last Page

786

Download

Share

COinS